A citation-based method for searching scientific literature

Sevin Turcan, Daniel Rohle, Anuj Goenka, Logan A Walsh, Fang Fang, Emrullah Yilmaz, Carl Campos, Armida W M Fabius, Chao Lu, Patrick S Ward, Craig B Thompson, Andrew Kaufman, Olga Guryanova, Ross Levine, Adriana Heguy, Agnes Viale, Luc G T Morris, Jason T Huse, Ingo K Mellinghoff, Timothy A Chan. Nature 2012
Times Cited: 1151







List of co-cited articles
929 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary.
David N Louis, Arie Perry, Guido Reifenberger, Andreas von Deimling, Dominique Figarella-Branger, Webster K Cavenee, Hiroko Ohgaki, Otmar D Wiestler, Paul Kleihues, David W Ellison. Acta Neuropathol 2016
42

IDH1 and IDH2 mutations in gliomas.
Hai Yan, D Williams Parsons, Genglin Jin, Roger McLendon, B Ahmed Rasheed, Weishi Yuan, Ivan Kos, Ines Batinic-Haberle, Siân Jones, Gregory J Riggins,[...]. N Engl J Med 2009
39

Cancer-associated IDH1 mutations produce 2-hydroxyglutarate.
Lenny Dang, David W White, Stefan Gross, Bryson D Bennett, Mark A Bittinger, Edward M Driggers, Valeria R Fantin, Hyun Gyung Jang, Shengfang Jin, Marie C Keenan,[...]. Nature 2009
33

IDH mutation impairs histone demethylation and results in a block to cell differentiation.
Chao Lu, Patrick S Ward, Gurpreet S Kapoor, Dan Rohle, Sevin Turcan, Omar Abdel-Wahab, Christopher R Edwards, Raya Khanin, Maria E Figueroa, Ari Melnick,[...]. Nature 2012
29

Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma.
Houtan Noushmehr, Daniel J Weisenberger, Kristin Diefes, Heidi S Phillips, Kanan Pujara, Benjamin P Berman, Fei Pan, Christopher E Pelloski, Erik P Sulman, Krishna P Bhat,[...]. Cancer Cell 2010
29

Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases.
Wei Xu, Hui Yang, Ying Liu, Ying Yang, Ping Wang, Se-Hee Kim, Shinsuke Ito, Chen Yang, Pu Wang, Meng-Tao Xiao,[...]. Cancer Cell 2011
26

Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas.
Daniel J Brat, Roel G W Verhaak, Kenneth D Aldape, W K Alfred Yung, Sofie R Salama, Lee A D Cooper, Esther Rheinbay, C Ryan Miller, Mark Vitucci, Olena Morozova,[...]. N Engl J Med 2015
22

Molecular Profiling Reveals Biologically Discrete Subsets and Pathways of Progression in Diffuse Glioma.
Michele Ceccarelli, Floris P Barthel, Tathiane M Malta, Thais S Sabedot, Sofie R Salama, Bradley A Murray, Olena Morozova, Yulia Newton, Amie Radenbaugh, Stefano M Pagnotta,[...]. Cell 2016
913
21

Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1.
Roel G W Verhaak, Katherine A Hoadley, Elizabeth Purdom, Victoria Wang, Yuan Qi, Matthew D Wilkerson, C Ryan Miller, Li Ding, Todd Golub, Jill P Mesirov,[...]. Cancer Cell 2010
19

An integrated genomic analysis of human glioblastoma multiforme.
D Williams Parsons, Siân Jones, Xiaosong Zhang, Jimmy Cheng-Ho Lin, Rebecca J Leary, Philipp Angenendt, Parminder Mankoo, Hannah Carter, I-Mei Siu, Gary L Gallia,[...]. Science 2008
17

Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation.
Maria E Figueroa, Omar Abdel-Wahab, Chao Lu, Patrick S Ward, Jay Patel, Alan Shih, Yushan Li, Neha Bhagwat, Aparna Vasanthakumar, Hugo F Fernandez,[...]. Cancer Cell 2010
17

The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases.
Rasheduzzaman Chowdhury, Kar Kheng Yeoh, Ya-Min Tian, Lars Hillringhaus, Eleanor A Bagg, Nathan R Rose, Ivanhoe K H Leung, Xuan S Li, Esther C Y Woon, Ming Yang,[...]. EMBO Rep 2011
622
17

An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells.
Dan Rohle, Janeta Popovici-Muller, Nicolaos Palaskas, Sevin Turcan, Christian Grommes, Carl Campos, Jennifer Tsoi, Owen Clark, Barbara Oldrini, Evangelia Komisopoulou,[...]. Science 2013
738
16


MGMT gene silencing and benefit from temozolomide in glioblastoma.
Monika E Hegi, Annie-Claire Diserens, Thierry Gorlia, Marie-France Hamou, Nicolas de Tribolet, Michael Weller, Johan M Kros, Johannes A Hainfellner, Warren Mason, Luigi Mariani,[...]. N Engl J Med 2005
15

Mutant IDH1 regulates the tumor-associated immune system in gliomas.
Nduka M Amankulor, Youngmi Kim, Sonali Arora, Julia Kargl, Frank Szulzewsky, Mark Hanke, Daciana H Margineantu, Aparna Rao, Hamid Bolouri, Jeff Delrow,[...]. Genes Dev 2017
158
13

Suppression of antitumor T cell immunity by the oncometabolite (R)-2-hydroxyglutarate.
Lukas Bunse, Stefan Pusch, Theresa Bunse, Felix Sahm, Khwab Sanghvi, Mirco Friedrich, Dalia Alansary, Jana K Sonner, Edward Green, Katrin Deumelandt,[...]. Nat Med 2018
123
13

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Roger Stupp, Warren P Mason, Martin J van den Bent, Michael Weller, Barbara Fisher, Martin J B Taphoorn, Karl Belanger, Alba A Brandes, Christine Marosi, Ulrich Bogdahn,[...]. N Engl J Med 2005
13

The somatic genomic landscape of glioblastoma.
Cameron W Brennan, Roel G W Verhaak, Aaron McKenna, Benito Campos, Houtan Noushmehr, Sofie R Salama, Siyuan Zheng, Debyani Chakravarty, J Zachary Sanborn, Samuel H Berman,[...]. Cell 2013
12

Hallmarks of cancer: the next generation.
Douglas Hanahan, Robert A Weinberg. Cell 2011
12

The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate.
Patrick S Ward, Jay Patel, David R Wise, Omar Abdel-Wahab, Bryson D Bennett, Hilary A Coller, Justin R Cross, Valeria R Fantin, Cyrus V Hedvat, Alexander E Perl,[...]. Cancer Cell 2010
11

Insulator dysfunction and oncogene activation in IDH mutant gliomas.
William A Flavahan, Yotam Drier, Brian B Liau, Shawn M Gillespie, Andrew S Venteicher, Anat O Stemmer-Rachamimov, Mario L Suvà, Bradley E Bernstein. Nature 2016
563
11

2-Hydroxyglutarate produced by neomorphic IDH mutations suppresses homologous recombination and induces PARP inhibitor sensitivity.
Parker L Sulkowski, Christopher D Corso, Nathaniel D Robinson, Susan E Scanlon, Karin R Purshouse, Hanwen Bai, Yanfeng Liu, Ranjini K Sundaram, Denise C Hegan, Nathan R Fons,[...]. Sci Transl Med 2017
224
11

Extreme Vulnerability of IDH1 Mutant Cancers to NAD+ Depletion.
Kensuke Tateishi, Hiroaki Wakimoto, A John Iafrate, Shota Tanaka, Franziska Loebel, Nina Lelic, Dmitri Wiederschain, Olivier Bedel, Gejing Deng, Bailin Zhang,[...]. Cancer Cell 2015
190
10

DNA methylation-based classification of central nervous system tumours.
David Capper, David T W Jones, Martin Sill, Volker Hovestadt, Daniel Schrimpf, Dominik Sturm, Christian Koelsche, Felix Sahm, Lukas Chavez, David E Reuss,[...]. Nature 2018
720
10

Recurring mutations found by sequencing an acute myeloid leukemia genome.
Elaine R Mardis, Li Ding, David J Dooling, David E Larson, Michael D McLellan, Ken Chen, Daniel C Koboldt, Robert S Fulton, Kim D Delehaunty, Sean D McGrath,[...]. N Engl J Med 2009
10

Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation.
Peppi Koivunen, Sungwoo Lee, Christopher G Duncan, Giselle Lopez, Gang Lu, Shakti Ramkissoon, Julie A Losman, Päivi Joensuu, Ulrich Bergmann, Stefan Gross,[...]. Nature 2012
489
9

Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas.
Marc Sanson, Yannick Marie, Sophie Paris, Ahmed Idbaih, Julien Laffaire, François Ducray, Soufiane El Hallani, Blandine Boisselier, Karima Mokhtari, Khe Hoang-Xuan,[...]. J Clin Oncol 2009
679
9

Transaminase Inhibition by 2-Hydroxyglutarate Impairs Glutamate Biosynthesis and Redox Homeostasis in Glioma.
Samuel K McBrayer, Jared R Mayers, Gabriel J DiNatale, Diana D Shi, Januka Khanal, Abhishek A Chakraborty, Kristopher A Sarosiek, Kimberly J Briggs, Alissa K Robbins, Tomasz Sewastianik,[...]. Cell 2018
108
9

Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML.
Courtney D DiNardo, Eytan M Stein, Stéphane de Botton, Gail J Roboz, Jessica K Altman, Alice S Mims, Ronan Swords, Robert H Collins, Gabriel N Mannis, Daniel A Pollyea,[...]. N Engl J Med 2018
524
9

Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis.
Heidi S Phillips, Samir Kharbanda, Ruihuan Chen, William F Forrest, Robert H Soriano, Thomas D Wu, Anjan Misra, Janice M Nigro, Howard Colman, Liliana Soroceanu,[...]. Cancer Cell 2006
9

Discovery of AG-120 (Ivosidenib): A First-in-Class Mutant IDH1 Inhibitor for the Treatment of IDH1 Mutant Cancers.
Janeta Popovici-Muller, René M Lemieux, Erin Artin, Jeffrey O Saunders, Francesco G Salituro, Jeremy Travins, Giovanni Cianchetta, Zhenwei Cai, Ding Zhou, Dawei Cui,[...]. ACS Med Chem Lett 2018
123
9

Isocitrate dehydrogenase mutations suppress STAT1 and CD8+ T cell accumulation in gliomas.
Gary Kohanbash, Diego A Carrera, Shruti Shrivastav, Brian J Ahn, Naznin Jahan, Tali Mazor, Zinal S Chheda, Kira M Downey, Payal B Watchmaker, Casey Beppler,[...]. J Clin Invest 2017
149
9

Efficient induction of differentiation and growth inhibition in IDH1 mutant glioma cells by the DNMT Inhibitor Decitabine.
Sevin Turcan, Armida W M Fabius, Alexandra Borodovsky, Alicia Pedraza, Cameron Brennan, Jason Huse, Agnes Viale, Gregory J Riggins, Timothy A Chan. Oncotarget 2013
143
8

Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation.
Fang Wang, Jeremy Travins, Byron DeLaBarre, Virginie Penard-Lacronique, Stefanie Schalm, Erica Hansen, Kimberly Straley, Andrew Kernytsky, Wei Liu, Camelia Gliser,[...]. Science 2013
541
8

Glioma Groups Based on 1p/19q, IDH, and TERT Promoter Mutations in Tumors.
Jeanette E Eckel-Passow, Daniel H Lachance, Annette M Molinaro, Kyle M Walsh, Paul A Decker, Hugues Sicotte, Melike Pekmezci, Terri Rice, Matt L Kosel, Ivan V Smirnov,[...]. N Engl J Med 2015
938
8

A heterozygous IDH1R132H/WT mutation induces genome-wide alterations in DNA methylation.
Christopher G Duncan, Benjamin G Barwick, Genglin Jin, Carlo Rago, Priya Kapoor-Vazirani, Doris R Powell, Jen-Tsan Chi, Darell D Bigner, Paula M Vertino, Hai Yan. Genome Res 2012
123
8

Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma.
Jeremy Schwartzentruber, Andrey Korshunov, Xiao-Yang Liu, David T W Jones, Elke Pfaff, Karine Jacob, Dominik Sturm, Adam M Fontebasso, Dong-Anh Khuong Quang, Martje Tönjes,[...]. Nature 2012
8

IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas.
Takuya Watanabe, Sumihito Nobusawa, Paul Kleihues, Hiroko Ohgaki. Am J Pathol 2009
654
8

Mutant Isocitrate Dehydrogenase Inhibitors as Targeted Cancer Therapeutics.
Danielle Golub, Nishanth Iyengar, Siddhant Dogra, Taylor Wong, Devin Bready, Karen Tang, Aram S Modrek, Dimitris G Placantonakis. Front Oncol 2019
91
8

Tumor Evolution of Glioma-Intrinsic Gene Expression Subtypes Associates with Immunological Changes in the Microenvironment.
Qianghu Wang, Baoli Hu, Xin Hu, Hoon Kim, Massimo Squatrito, Lisa Scarpace, Ana C deCarvalho, Sali Lyu, Pengping Li, Yan Li,[...]. Cancer Cell 2017
499
8

(R)-2-hydroxyglutarate is sufficient to promote leukemogenesis and its effects are reversible.
Julie-Aurore Losman, Ryan E Looper, Peppi Koivunen, Sungwoo Lee, Rebekka K Schneider, Christine McMahon, Glenn S Cowley, David E Root, Benjamin L Ebert, William G Kaelin. Science 2013
456
7

Pan-mutant IDH1 inhibitor BAY 1436032 for effective treatment of IDH1 mutant astrocytoma in vivo.
Stefan Pusch, Sonja Krausert, Viktoria Fischer, Jörg Balss, Martina Ott, Daniel Schrimpf, David Capper, Felix Sahm, Jessica Eisel, Ann-Christin Beck,[...]. Acta Neuropathol 2017
91
7

Biological Role and Therapeutic Potential of IDH Mutations in Cancer.
Matthew S Waitkus, Bill H Diplas, Hai Yan. Cancer Cell 2018
104
7

cIMPACT-NOW update 3: recommended diagnostic criteria for "Diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV".
Daniel J Brat, Kenneth Aldape, Howard Colman, Eric C Holland, David N Louis, Robert B Jenkins, B K Kleinschmidt-DeMasters, Arie Perry, Guido Reifenberger, Roger Stupp,[...]. Acta Neuropathol 2018
248
7

Frequent ATRX mutations and loss of expression in adult diffuse astrocytic tumors carrying IDH1/IDH2 and TP53 mutations.
Xiao-Yang Liu, Noha Gerges, Andrey Korshunov, Nesrin Sabha, Dong-Anh Khuong-Quang, Adam M Fontebasso, Adam Fleming, Djihad Hadjadj, Jeremy Schwartzentruber, Jacek Majewski,[...]. Acta Neuropathol 2012
244
7

Radioprotection of IDH1-Mutated Cancer Cells by the IDH1-Mutant Inhibitor AGI-5198.
Remco J Molenaar, Dennis Botman, Myrthe A Smits, Vashendriya V Hira, Sanne A van Lith, Jan Stap, Peter Henneman, Mohammed Khurshed, Krissie Lenting, Adri N Mul,[...]. Cancer Res 2015
85
8

Analysis of the IDH1 codon 132 mutation in brain tumors.
Jörg Balss, Jochen Meyer, Wolf Mueller, Andrey Korshunov, Christian Hartmann, Andreas von Deimling. Acta Neuropathol 2008
727
7

5-azacytidine reduces methylation, promotes differentiation and induces tumor regression in a patient-derived IDH1 mutant glioma xenograft.
Alexandra Borodovsky, Vafi Salmasi, Sevin Turcan, Armida W M Fabius, Gilson S Baia, Charles G Eberhart, Jon D Weingart, Gary L Gallia, Stephen B Baylin, Timothy A Chan,[...]. Oncotarget 2013
100
7

Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles.
Aravind Subramanian, Pablo Tamayo, Vamsi K Mootha, Sayan Mukherjee, Benjamin L Ebert, Michael A Gillette, Amanda Paulovich, Scott L Pomeroy, Todd R Golub, Eric S Lander,[...]. Proc Natl Acad Sci U S A 2005
7


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.